Parnax Lab Valuation
Is 506128 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 506128 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 506128 (₹136.1) is trading below our estimate of fair value (₹140.39)
Significantly Below Fair Value: 506128 is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 506128?
Other financial metrics that can be useful for relative valuation.
| What is 506128's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | ₹1.56b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.2x |
| Enterprise Value/EBITDA | 9.7x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 506128's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 34.4x | ||
531569 Sanjivani Paranteral | 30.3x | n/a | ₹1.8b |
SOTAC Sotac Pharmaceuticals | 43x | n/a | ₹1.3b |
524824 Bal Pharma | 44.3x | n/a | ₹1.6b |
524828 BDH Industries | 19.9x | n/a | ₹1.8b |
506128 Parnax Lab | 17.7x | n/a | ₹1.6b |
Price-To-Earnings vs Peers: 506128 is good value based on its Price-To-Earnings Ratio (17.7x) compared to the peer average (34.4x).
Price to Earnings Ratio vs Industry
How does 506128's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?
Price-To-Earnings vs Industry: 506128 is good value based on its Price-To-Earnings Ratio (17.7x) compared to the Indian Pharmaceuticals industry average (32.2x).
Price to Earnings Ratio vs Fair Ratio
What is 506128's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 17.7x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 506128's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.